Effect of colonoscopy outreach vs fecal immunochemical test outreach on colorectal cancer screening completion a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 9, 2017, Pages 806-815

  Singal, Amit G ^a,b,c   Gupta, Samir ^d,e   Skinner, Celette Sugg ^a,c   Ahn, Chul ^a,c   Santini, Noel O ^b   Agrawal, Deepak ^a   Mayorga, Christian A ^a   Murphy, Caitlin ^a   Tiro, Jasmin A ^a,c   McCallister, Katharine ^a   Sanders, Joanne M ^a   Bishop, Wendy Pechero ^a,c   Loewen, Adam C ^a   Halm, Ethan A ^a,b,c  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMA; ADULT; ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL OUTCOME; COLON HEMORRHAGE; COLON PERFORATION; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OCCULT BLOOD TEST; OCCULT BLOOD TEST KIT; PATIENT SAFETY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; HEALTH PROMOTION; MASS SCREENING; OCCULT BLOOD; PROCEDURES; SAFETY NET HOSPITAL; UTILIZATION;

COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HEALTH PROMOTION; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; SAFETY-NET PROVIDERS;

EID: 85028910005     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.11389     Document Type: Article

References (38)

1. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):2564-2575.
2. Gupta S, Halm EA, Rockey DC, et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Intern Med. 2013;173(18):1725-1732.
3. White A, Thompson TD, White MC, et al. Cancer screening test use-United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):201-206.
4. Fenton JJ, Elmore JG, Buist DS, Reid RJ, Tancredi DJ, Baldwin LM. Longitudinal adherence with fecal occult blood test screening in community practice. Ann FamMed. 2010;8(5):397-401.
5. Liss DT, Petit-Homme A, Feinglass J, Buchanan DR, Baker DW. Adherence to repeat fecal occult blood testing in an urban community health center network. J Community Health. 2013;38(5):829-833.
6. Chubak J, Garcia MP, Burnett-Hartman AN, et al; PROSPR consortium. Time to colonoscopy after positive fecal blood test in 4 US health care systems. Cancer Epidemiol Biomarkers Prev. 2016;25(2):344-350.
7. Martin J, Halm EA, Tiro JA, et al. Reasons for lack of diagnostic colonoscopy after positive result on fecal immunochemical test in a safety-net health system. Am J Med. 2017;130(1):93.e1-93.e7.
8. Hawley ST, McQueen A, Bartholomew LK, et al. Preferences for colorectal cancer screening tests and screening test use in a large multispecialty primary care practice. Cancer. 2012;118(10):2726-2734.
9. Wheeler SB, Kuo TM, Meyer AM, et al. Multilevel predictors of colorectal cancer testing modality among publicly and privately insured people turning 50. Prev Med Rep. 2016;6:9-16.
10. Green BB, Anderson ML, Wang CY, et al. Results of nurse navigator follow-up after positive colorectal cancer screening test: a randomized trial. J AmBoard Fam Med. 2014;27(6):789-795.
11. Singh H, Kadiyala H, Bhagwath G, et al. Using a multifaceted approach to improve the follow-up of positive fecal occult blood test results. Am J Gastroenterol. 2009;104(4):942-952.
12. Tiro JA, Kamineni A, Levin TR, et al. The colorectal cancer screening process in community settings: a conceptual model for the population-based research optimizing screening through personalized regimens consortium. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1147-1158.
13. Singal AG, Gupta S, Tiro JA, et al. Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: a randomized controlled trial in a safety-net health system. Cancer. 2016;122(3):456-463.
14. Stegeman I, van Doorn SC, Mundt MW, et al. Participation, yield, and interval carcinomas in 3 rounds of biennial FIT-based colorectal cancer screening. Cancer Epidemiol. 2015;39(3):388-393.
15. Goebel M, Singal AG, Nodora J, et al. How can we boost colorectal and hepatocellular cancer screening among underserved populations? Curr Gastroenterol Rep. 2015;17(6):22.
16. Quintero E, Castells A, Bujanda L, et al; COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366(8):697-706.
17. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
18. Seeff LC, Manninen DL, Dong FB, et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? Gastroenterology. 2004;127(6):1661-1669.
19. Xu Y, Levy BT, Daly JM, Bergus GR, Dunkelberg JC. Comparison of patient preferences for fecal immunochemical test or colonoscopy using the analytic hierarchy process. BMC Health Serv Res. 2015;15:175.
20. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575-582.
21. Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst. 2011;103(23):1741-1751.
22. Denis B, Gendre I, Sauleau EA, Lacroute J, Perrin P. Harms of colonoscopy in a colorectal cancer screening programme with faecal occult blood test: a population-based cohort study. Dig Liver Dis. 2013;45(6):474-480.
23. Heleno B, Thomsen MF, Rodrigues DS, Jorgensen KJ, Brodersen J. Quantification of harms in cancer screening trials: literature review. BMJ. 2013;347:f5334.
24. Schoen RE, Pinsky PF, Weissfeld JL, et al. Utilization of surveillance colonoscopy in community practice. Gastroenterology. 2010;138(1):73-81.
25. Cooper GS, Kou TD, Barnholtz Sloan JS, Koroukian SM, Schluchter MD. Use of colonoscopy for polyp surveillance in Medicare beneficiaries. Cancer. 2013;119(10):1800-1807.
26. Kahn B, Freeland Z, Gopal P, et al. Predictors of guideline concordance for surveillance colonoscopy recommendations in patients at a safety-net health system. Cancer Causes Control. 2015;26(11):1653-1660.
27. Janda M, Hughes KL, Auster JF, Leggett BA, Newman BM. Repeat participation in colorectal cancer screening utilizing fecal occult blood testing: a community-based project in a rural setting. J Gastroenterol Hepatol. 2010;25(10):1661-1667.
28. Ferrat E, Le Breton J, Veerabudun K, et al. Colorectal cancer screening: factors associated with colonoscopy after a positive faecal occult blood test. Br J Cancer. 2013;109(6):1437-1444.
29. Paszat L, Rabeneck L, Kiefer L, Mai V, Ritvo P, Sullivan T. Endoscopic follow-up of positive fecal occult blood testing in the Ontario FOBT Project. Can J Gastroenterol. 2007;21(6):379-382.
30. Cavanagh MF, Lane DS, Messina CR, Anderson JC. Clinical case management and navigation for colonoscopy screening in an academic medical center. Cancer. 2013;119(suppl 15):2894-2904.
31. Wilson FA, Villarreal R, Stimpson JP, Pagán JA. Cost-effectiveness analysis of a colonoscopy screening navigator program designed for Hispanic men. J Cancer Educ. 2015;30(2):260-267.
32. Fedewa SA, Goodman M, Flanders WD, et al. Elimination of cost-sharing and receipt of screening for colorectal and breast cancer. Cancer. 2015;121(18):3272-3280.
33. Baker DW, Brown T, Buchanan DR, et al. Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1235-1241.
34. US Preventive Services Task Force. Archived evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force. https://www.uspreventiveservicestaskforce.org/Page/SupportingDoc/colorectal-cancer-screening/evaluating-test-strategies-for-colorectal-cancer-screening-a-decision-analysis-for-the-us-preventive-services-task-force. Accessed August 4, 2017.
35. Barry MJ, Edgman-Levitan S. Shared decision making-pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780-781.
36. Oshima Lee E, Emanuel EJ. Shared decision making to improve care and reduce costs. N Engl J Med. 2013;368(1):6-8.
37. Joosten EA, DeFuentes-Merillas L, deWeert GH, Sensky T, van der Staak CP, de Jong CA. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom. 2008;77(4):219-226.
38. Liang PS, Wheat CL, Abhat A, et al. Adherence to competing strategies for colorectal cancer screening over 3 years. Am J Gastroenterol. 2016;111(1):105-114.